Genizon rounds up $31M
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Genizon BioSciences
|
$31M
|
BTF |
Genizon's has DNA resources and a platform that is applicable to many stages of drug development. |
|
Corthera
|
$23M
|
Caxton Advantage Life Sciences Fund |
Corthera lead therapy is Relaxin, which is being developed to treat heart failure. |
|
Primera Biosystems
|
$21M
|
Abingworth |
Primera has been developing new technology related to gene expression, DNA/RNA analysis, micro RNA analysis, mutation analysis and methylated DNA analysis. |
|
Arcion Therapeutics
|
$8.8M
|
CMEA Ventures and InterWest Partners |
Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy. |
|
Follica
|
$5.5M
|
Interwest Partners |
Follica is developing a therapy for androgenetic alopecia and other hair follicle disorders. |